Abstract
With recent approvals for multiple therapeutic antibodies that block cytotoxic T lymphocyte associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) in melanoma, non-small-cell lung cancer and kidney cancer, and additional immune checkpoints being targeted clinically, many questions still remain regarding the optimal use of drugs that block these checkpoint pathways. Defining biomarkers that predict therapeutic effects and adverse events is a crucial mandate, highlighted by recent approvals for two PDL1 diagnostic tests. Here, we discuss biomarkers for anti-PD1 therapy based on immunological, genetic and virological criteria. The unique biology of the CTLA4 immune checkpoint, compared with PD1, requires a different approach to biomarker development. Mechanism-based insights from such studies may guide the design of synergistic treatment combinations based on immune checkpoint blockade.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 275-287 |
| Number of pages | 13 |
| Journal | Nature Reviews Cancer |
| Volume | 16 |
| Issue number | 5 |
| DOIs | |
| State | Published - Apr 26 2016 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. / Topalian, Suzanne; Taube, Janis M; Anders, Robert A; Pardoll, Andrew Mark.
In: Nature Reviews Cancer, Vol. 16, No. 5, 26.04.2016, p. 275-287.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
AU - Topalian, Suzanne
AU - Taube, Janis M
AU - Anders, Robert A
AU - Pardoll, Andrew Mark
PY - 2016/4/26
Y1 - 2016/4/26
N2 - With recent approvals for multiple therapeutic antibodies that block cytotoxic T lymphocyte associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) in melanoma, non-small-cell lung cancer and kidney cancer, and additional immune checkpoints being targeted clinically, many questions still remain regarding the optimal use of drugs that block these checkpoint pathways. Defining biomarkers that predict therapeutic effects and adverse events is a crucial mandate, highlighted by recent approvals for two PDL1 diagnostic tests. Here, we discuss biomarkers for anti-PD1 therapy based on immunological, genetic and virological criteria. The unique biology of the CTLA4 immune checkpoint, compared with PD1, requires a different approach to biomarker development. Mechanism-based insights from such studies may guide the design of synergistic treatment combinations based on immune checkpoint blockade.
AB - With recent approvals for multiple therapeutic antibodies that block cytotoxic T lymphocyte associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) in melanoma, non-small-cell lung cancer and kidney cancer, and additional immune checkpoints being targeted clinically, many questions still remain regarding the optimal use of drugs that block these checkpoint pathways. Defining biomarkers that predict therapeutic effects and adverse events is a crucial mandate, highlighted by recent approvals for two PDL1 diagnostic tests. Here, we discuss biomarkers for anti-PD1 therapy based on immunological, genetic and virological criteria. The unique biology of the CTLA4 immune checkpoint, compared with PD1, requires a different approach to biomarker development. Mechanism-based insights from such studies may guide the design of synergistic treatment combinations based on immune checkpoint blockade.
UR - http://www.scopus.com/inward/record.url?scp=84963621254&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84963621254&partnerID=8YFLogxK
U2 - 10.1038/nrc.2016.36
DO - 10.1038/nrc.2016.36
M3 - Article
C2 - 27079802
AN - SCOPUS:84963621254
VL - 16
SP - 275
EP - 287
JO - Nature Reviews Cancer
JF - Nature Reviews Cancer
SN - 1474-175X
IS - 5
ER -